ICC to hear breast cancer drug dispute
A Los Angeles biopharmaceutical company has launched an ICC claim over a US$195 million licence agreement to promote a breast cancer drug in Greater China.
To read more
Subscribe to Global Arbitration Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Arbitration Review experts.